A 1XX-enhanced and fully non-viral BCMA CAR T cell therapy for Relapsed and Refractory Multiple Myeloma (UCCT-BCMA-1)

Return to Grants

Grant Award Details

Grant Number:
CLIN1-15060
Investigator(s):
Human Stem Cell Use:
Award Value:
$4,585,501
Status:
Pre-Active

Grant Application Details

Application Title:

A 1XX-enhanced and fully non-viral BCMA CAR T cell therapy for Relapsed and Refractory Multiple Myeloma (UCCT-BCMA-1)

Public Abstract:
Therapeutic Candidate or Device

Cryopreserved autologous TRAC locus 1XX BCMA-CAR T cells

Indication

Relapsed and Refractory Multiple Myeloma

Therapeutic Mechanism

Engineered T cells target and kill BCMA+ Myeloma cells

Unmet Medical Need

No durable treatments are available for RRMM and only ~30% of patients can access current BCMA CAR therapies. This product can improve product safety, potency, and persistence, and enable treatment for patients without access to FDA-approved CAR-T therapies.

Project Objective

Approved IND for Phase 1 trial.

Major Proposed Activities

  • Manufacturing process development and validation
  • Completion of pre-clinical pharmacology and toxicology studies
  • IND submission
Statement of Benefit to California:
MM is a common and incurable disease with >3,000 new cases and >1,300 deaths yearly in CA. Despite new treatments, patients inevitably relapse and exhaust all treatment options. We will incorporate innovations in CAR-T cell design and CRISPR-mediated transgene insertion to generate an improved BCMA CAR T cell therapy, enhancing safety, purity, potency, and persistence. This therapy will be made available to diverse California patients who lack access to current FDA-approved therapies.